Industry News

The latest news from the clinical trials industry.

News Powered By:

- a collaborative partner.


HHS, NIH to enhance transparency of clinical trial results

CenterWatch News Online Headlines : November 21, 2014 5:31 am : Centerwatch

The U.S. Department of Health and Human Services has issued a Notice of Proposed Rulemaking (NPRM), which proposes regulations to reporting requirements for clinical trials subject to Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA).

U.K. launches Innovative Medicines Review

CenterWatch News Online Headlines : November 21, 2014 5:27 am : Centerwatch

The U.K. government is launching an Innovative Medicines Review, which will consider how to speed up patient access to cost-effective and innovative medicines, devices and diagnostics.

Australia, New Zealand cancel agreement for joint therapeutic regulator

CenterWatch News Online Headlines : November 21, 2014 5:21 am : Centerwatch

Peter Dutton, MP, Minister for Health for Australia, and the Jonathan Coleman, Minister of Health for New Zealand, have announced their governments’ agreement to cease efforts to establish a joint therapeutic products regulator, the Australia New Zealand Therapeutic Products Agency (ANZTPA).

OncoSec Medical, University of Washington ink research agreement

CenterWatch News Online Headlines : November 21, 2014 5:20 am : Centerwatch

OncoSec Medical, a San Diego-based company developing DNA-based intratumoral cancer immunotherapies, has entered a sponsored research agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.

EMA revises policy on conflicts of interest

CenterWatch News Online Headlines : November 21, 2014 5:19 am : Centerwatch

The EMA has published its revised policy on handling declarations of interests for scientific committee members and experts. The revisions reflect a more balanced approach to handling conflicts of interests that aims to effectively restrict the involvement of experts with possible conflicts of interests in the agency’s work, while maintaining EMA’s ability to access the best available expertise.

« Page 1, 2, 3486 »